美国批准Teva的骨质疏松生物类似药PONLIMSI. Teva wins US approval for osteoporosis biosimilar PONLIMSI.

美国已批准Teva Pharmaceutical公司的生物类似药PONLIMSI治疗骨质疏松症. Teva Pharmaceutical has received U.S. approval for its biosimilar PONLIMSI, which treats osteoporosis. 该公司还看到其申请Xolair生物类似药被美国和欧洲监管机构接受. The company also saw its application for a biosimilar to Xolair accepted by both U.S. and European regulators. 这些步骤突出了Teva在生物类似药市场的进步. These steps highlight Teva's progress in the biosimilars market.